Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 5:25 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 3,459 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Metabolic Effects Clear all

Conditions: Obesity, Weight Loss, Diet Modification, Aging, Weight Change, Body, Dietary Habits, Osteopenia, Osteoporosis, Bone Loss, Fractures, Bone
Interventions: Weight loss intervention months 0-6, Exercise intervention months 0-6, NutraBio™ CarboMax Supplement, 6-month NutraBio™ 100% Whey Protein Isolate Supplement, 18-month NutraBio™ 100% Whey Protein Isolate Supplement; Behavioral · Dietary Supplement
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 65 Years to 85 Years
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Hypertriglyceridemia
Interventions: Amino acids, Placebo; Dietary Supplement
Lead sponsor: University of Arkansas; Other
Eligibility: 50 Years to 75 Years
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Thyroid Nodules, Hypocalcemia
Interventions: Calcitriol, Control Pill; Dietary Supplement
Lead sponsor: David Shonka, MD; Other
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Diabetes Mellitus, Type 2
Interventions: ORMD-0801, Placebo; Drug · Other
Lead sponsor: Oramed, Ltd.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Tustin, California

Conditions: Hepatic Encephalopathy
Interventions: Rifaximin, placebo; Drug
Lead sponsor: Hunter Holmes Mcguire Veteran Affairs Medical Center; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Type II Diabetes, Atherosclerosis
Interventions: Tirzepatide, Placebo; Drug
Lead sponsor: Matthew J. Budoff; Other
Eligibility: 40 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Torrance, California

Conditions: PreDiabetes, Aging
Interventions: Moderate Intensity Exercise Training (MOD), Vigorous Intensity Exercise Training (VIG); Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 60 Years to 79 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Mucopolysaccharidosis IVA, Morquio A Syndrome, MPS IVA
Interventions: BMN 110; Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 7 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 4
States / cities: Oakland, California • Chicago, Illinois • New York, New York + 1 more

Conditions: Obesity (Disorder)
Interventions: Normobaric hypoxia (NH), Normobaric normoxia (NN); Other
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 22 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Elevated Body Mass Index
Interventions: LIK066, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Obesity, Weight Loss
Interventions: Weight Stable Group; Behavioral
Lead sponsor: Wake Forest University; Other
Eligibility: 65 Years to 79 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Breast Cancer, Osteoporosis
Interventions: letrozole, zoledronic acid; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Cardiomyopathy, Heart Failure With Preserved Ejection Fraction (HFpEF), Obesity
Interventions: Semaglutide, Placebo, Counselling on healthy lifestyle intervention; Drug · Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Impaired Glucose Tolerance, Prediabetes
Interventions: CGM; Device
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 10 Years to 18 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Prediabetes
Interventions: ≥10,000 daily steps (≥5 days/week) and stopping evening snacking; Behavioral
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 12 Years to 18 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Sleep, Body Composition, Strength, Insulin Sensitivity, Energy Expenditure
Interventions: Whey protein, Omega-3 fatty acids; Dietary Supplement
Lead sponsor: University of Arkansas, Fayetteville; Other
Eligibility: Up to 85 Years · Female only
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Fayetteville, Arkansas

Conditions: Diabetes, Depression
Interventions: sertraline, Placebo; Drug
Lead sponsor: Charles Drew University of Medicine and Science; Other
Eligibility: 21 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Type 2 Diabetes
Interventions: Not listed
Lead sponsor: HealthPartners Institute; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 5
States / cities: Boston, Massachusetts • Minneapolis, Minnesota • Las Vegas, Nevada + 2 more

Conditions: Shoulder Surgery, Obesity
Interventions: Ultrasound-Guided Interscalene Brachial Plexus Block, Phrenic-Sparing Block Combination (Experimental), Bupivacaine HCl 0.5% Injectable Solution, Dexamethasone 4mg; Procedure · Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin detemir; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 66
States / cities: Goodyear, Arizona • Scottsdale, Arizona • Searcy, Arkansas + 55 more

Conditions: Hypercholesterolemia
Interventions: Evolocumab, Placebo; Biological · Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 970 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 59
States / cities: Huntsville, Alabama • Mobile, Alabama • Little Rock, Arkansas + 54 more

Conditions: Obesity
Interventions: Transcranial Direct Current Stimulation (tDCS); Device
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 20 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Metabolic Acidosis
Interventions: TRC101, Placebo; Drug
Lead sponsor: Tricida, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 7
States / cities: Phoenix, Arizona • Los Angeles, California • Hialeah, Florida + 4 more

Conditions: Ataxia Telangiectasia
Interventions: Dexamethasone sodium phosphate, Placebo; Drug · Other
Lead sponsor: Quince Therapeutics S.p.A.; Industry
Eligibility: 6 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: Los Angeles, California • Baltimore, Maryland • Cincinnati, Ohio + 1 more

Search by objective public record fields.

Utilizing Protein During Weight Loss to Impact Physical Function and Bone

Effects of Amino Acids on Regional Lipid Metabolism

Phase II Pre-operative Vitamin D Supplementation to Prevent Post-thyroidectomy Hypocalcemia

A Study to Evaluate the Effect of ORMD-0801 in Patients With Type 2 Diabetes Mellitus

Rifaximin in Minimal Hepatic Encephalopathy

Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT

Effects of Progressive Intensity Exercise Training on Glycemic Control in Older Adults

Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome

Iron Absorption in The Low Oxygen Exposure and Weight Status (LOWS) Study

Effect of LIK066 on Body Weight in Patients With Elevated Body Mass Index

Effect of High Protein Weight Loss for Seniors

Letrozole With or Without Zoledronate in Treating Healthy Postmenopausal Women With High Breast Density

Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction

CGM and Lifestyle Changes in Patients With Impaired Glucose Tolerance

Effect of Increased Physical Activity and Stopping Evening Snacking in Metabolic Health in Youth With Prediabetes

Nutrition, Body Composition, and Sleep

Treatment of Diabetes and Depression in Hispanics and African Americans and Its Effect on A1c and Quality of Life.

Use of Continuous Glucose Monitoring Combined With Ambulatory Glucose Profiles to Characterize Glycemic Control

Interscalene vs Phrenic-sparing Blocks in Obesity and Effect of Maximum Inspiratory Pressure

Effect of Two Different Fasting Blood Glucose Targets on Glucose Control in Patients With Type 2 Diabetes Using Insulin Detemir Once Daily

GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound

Enhancement of Brain Circuit of Inhibitory Control in Obese Patients Undergoing Gastric Banding

Long-term Safety Extension to Study TRCA-301

Evaluate the Neurological Effects of EryDex on Subjects With A-T